Rob Wright - Chief Editor

Rob Wright

Rob Wright

Rob Wright is the chief editor of Life Science Leader magazine. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, co-chaired, moderated, and served as a speaker at industry and academic conferences and is the past co-chair for the 2015 BIO International conference educational planning committee. Wright’s 100+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma.

ROB'S WORK

  • Despite Delays, JPM 2017 Still Pays Off For Me
    Despite Delays, JPM 2017 Still Pays Off For Me

    For the second year in a row my travel plans to the biopharmaceutical industry’s yearly kickoff event — the 35th Annual J. P. Morgan Healthcare Conference in San Francisco —was disrupted by weather. And though I once again arrived a day late, there was still plenty to keep me busy during JPM. For example, I still had the opportunity to sit in breakout Q&A sessions involving Alkermes, BMS, Chimerix, GSK, Mylan NV, and Shire. I witnessed company presentations that included AbbVie, CSL Limited, and IDEXX (just to name a few). I attended keynotes involving the Vice President of the United States, Joe Biden, who provided an update on the Cancer Moonshot initiative. I heard political consultants Karl Rove and James Carville debate the pros and cons of repealing and replacing the Affordable Care Act. I even had the opportunity to hear Juan Enriquez, co-author of Evolving Ourselves, share his insights on the next species of human. And while this may seem like a lot, it really only scratches the surface as to the amount of activity that takes place during JPM in January.

9 Questions With Takeda Oncology’s Chief Counsel And Head Of Patient Advocacy

In 2002 Liz Lewis joined Takeda where she is currently chief counsel and head of patient advocacy at Takeda Oncology. Lewis sat down with me to share how she helped enhance Takeda Oncology’s patient advocacy organization.

What You Need To Know About Being Ready To Join A Board

Chief Editor Rob Wright talks with a few pharma industry icons about what to expect when seeking a board appointment.

How Boehringer Ingelheim Is Redefining Its R&D Strategy

In November 2015, Boehringer Ingelheim (BI) announced its new five-year R&D strategy, which included a commitment to invest $11 billion. Clive Wood, Ph.D., SVP of discovery research at BI, sat down with Life Science Leader to explain how the company is redefining its R&D strategy in order to maximize internal potential and expand research “for and beyond therapeutic area borders.”

Inside Takeda Oncology’s Patient Advocacy Program

So how does a lawyer become head of patient advocacy at one of the largest biopharma companies in the world? In Liz Lewis’s case, it started at the Washington, DC-based law firm, Epstein, Becker and Green where she represented healthcare and life sciences companies and served as cochair for the firm’s pharmaceutical practice group.

What Will The Global Biopharmaceutical Industry Look Like In 2027: Trendsetter Series Part 4 of 4

The executive-level participation for Life Science Leader magazine's signature 2017 Outlook issue had an overwhelming. This year’s feature article involved 13 executive life science leaders! In part four of this series, which is a supplement to the feature magazine article, we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?”

Shire CEO and Novartis CMO Weigh In On Trends For 2017: Trendsetter Series Part 3 of 4

The December 2016 issue of Life Science Leader magazine raised the bar in our 2017 Outlook feature article with participation from 13 trendsetters, including pharma leaders, payors, and a representative from the NIH. We hope you enjoy reading their thoughts in this supplement to the magazine’s December 2016 cover feature.

How Biopharmas Are Addressing Key Trends For 2017: Trendsetter Series Part 2 of 4

When Life Science Leader magazine asked for executive-level participation for the signature 2017 Outlook issue published in December 2016, we were overwhelmed with the response. This year’s feature article involved 13 executive thought leaders! In part two of this series, which is a supplement to the 2017 Outlook feature article, we pose the question, “What are you doing at your organization to address/capitalize on certain trends?” 

What Trends Will Have The Biggest Impact On Biopharma In 2017: Trendsetter Series Part 1 of 4

When Life Science Leader magazine asked executives to participate in our signature 2017 Outlook issue published in December 2016, the response was overwhelming. We gained participation from 13 life science leaders! But one of the challenges such a positive response creates is it makes it impossible to publish all of this great content.

What 13 Life Science Trendsetters Expect For 2017 And Beyond

The sharing of this knowledge is meant not merely to provide you wisdom, but hopefully inspire insight.